A photo collage featuring the DETERMINE logo, a mother and son, and two scientists comparing results

DETERMINE is the first UK national precision medicine trial in rare cancers, testing a range of therapies specifically targeting key genetic changes in cancer cells.

More information for patients about how they can join the trial and participating centres will be available soon.

Working together

The DETERMINE trial is led by the University of Manchester and is sponsored and managed by Cancer Research UK’s Centre for Drug Development. It is run in collaboration with the University of Birmingham, the Royal Marsden NHS Foundation Trust and the Christie NHS Foundation Trust.


Meet the team

Photo of Dr Matthew Krebs

Dr Matthew Krebs
Chief Investigator
University of Manchester

Photo of Dr Lynley Marshall

Dr Lynley Marshall
Paediatric Lead
Royal Marsden Hospital

Photo of Professor Gary Middleton

Professor Gary Middleton
Translational Lead
University of Birmingham

Photo of Professor Lucinda Billingham

Professor Lucinda Billingham
Statistical Lead
University of Birmingham

Learn more about the DETERMINE trial

Members of the DETERMINE team will be at the upcoming ‘AACR Annual Meeting 2022’ and the ‘2022 ASCO Annual Meeting’. If you are interested in meeting us at either of those events please get in touch via the enquiry form above.

Read the press release